Bavarian Nordic (OTCMKTS:BVNRY) Short Interest Up 233.4% in May

Bavarian Nordic (OTCMKTS:BVNRY) saw a significant growth in short interest in the month of May. As of May 29th, there was short interest totaling 14,745 shares, a growth of 233.4% from the May 14th total of 4,423 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 6,576 shares, the short-interest ratio is presently 2.2 days.

Bavarian Nordic Stock Performance

Shares of OTCMKTS BVNRY remained flat at $9.38 during midday trading on Thursday. 283 shares of the company were exchanged, compared to its average volume of 2,695. The firm has a market capitalization of $2.23 billion, a P/E ratio of 12.34 and a beta of 1.19. The stock’s 50 day moving average is $9.91 and its 200-day moving average is $9.93. Bavarian Nordic has a fifty-two week low of $8.66 and a fifty-two week high of $13.00.

Bavarian Nordic (OTCMKTS:BVNRY) last announced its earnings results on Wednesday, May 13th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $165.70 million during the quarter. Bavarian Nordic had a net margin of 19.74% and a return on equity of 9.37%.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.